Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Reece, Kelie M ^a   Richardson, Emily D ^a   Cook, Kristina M ^a   Campbell, Tessa J ^a   Pisle, Stephen T ^b   Holly, Alesia J ^a   Venzon, David J ^a   Liewehr, David J ^a   Chau, Cindy H ^a   Price, Douglas K ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Angiogenesis; ETPs; HIF 1 ; Hypoxia; p300; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; CHETOCIN; CHETOMIN; E1A ASSOCIATED P300 PROTEIN; EPIDITHIODIKETOPIPERAZINE; GLIOTOXIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PIPERAZINE DERIVATIVE; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN; CHAETOCIN; DISULFIDE; DNA BINDING PROTEIN; ENO1 PROTEIN, HUMAN; ENOLASE; EP300 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; INDOLE ALKALOID; ISOENZYME; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE 5; MESSENGER RNA; PROTEIN BINDING; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS ASSAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL LYSATE; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE TARGETING; HCT116 CELL LINE; HOUSEKEEPING GENE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LIVER CELL CARCINOMA; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; TUMOR GROWTH; TUMOR XENOGRAFT; VASCULAR RING; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECTS; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISULFIDES; DNA-BINDING PROTEINS; E1A-ASSOCIATED P300 PROTEIN; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOTOXIN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDOLE ALKALOIDS; ISOENZYMES; L-LACTATE DEHYDROGENASE; MALE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOPYRUVATE HYDRATASE; PIPERAZINES; PROSTATIC NEOPLASMS; PROTEIN BINDING; RATS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84900029890     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-91     Document Type: Article

References (36)

1. Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev 2011, 63:623-639. 10.1016/j.addr.2010.11.005, 21144874.
2. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008, 8:425-437. 10.1038/nrc2397, 3943205, 18500244.
3. Patiar S, Harris AL. Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr Relat Cancer 2006, 13(Suppl 1):S61-S75.
4. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732. 10.1038/nrc1187, 13130303.
5. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634. 10.1038/onc.2009.441, 2969168, 19946328.
6. Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004, 3:647-654.
7. Xia Y, Choi HK, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 2012, 49:24-40.
8. Otrock ZK, Hatoum HA, Awada AH, Ishak RS, Shamseddine AI. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol 2009, 70:93-102. 10.1016/j.critrevonc.2009.01.001, 19186072.
9. Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW. Hypoxia-inducible factor (HIF-1) alpha: its protein stability and biological functions. Exp Mol Med 2004, 36:1-12. 10.1038/emm.2004.1, 15031665.
10. Wang R, Zhou S, Li S. Cancer therapeutic agents targeting hypoxia-inducible factor-1. Curr Med Chem 2011, 18:3168-3189. 10.2174/092986711796391606, 21671859.
11. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9:677-684. 10.1038/nm0603-677, 12778166.
12. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987, 235:442-447. 10.1126/science.2432664, 2432664.
13. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31. 10.1038/nm0195-27, 7584949.
14. Hong SS, Lee H, Kim KW. HIF-1alpha: a valid therapeutic target for tumor therapy. Cancer Res Treat 2004, 36:343-353. 10.4143/crt.2004.36.6.343, 2843877, 20368827.
15. Rey S, Semenza GL. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res 2010, 86:236-242. 10.1093/cvr/cvq045, 2856192, 20164116.
16. Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 2009, 13:2780-2786. 10.1111/j.1582-4934.2009.00876.x, 2832082, 19674190.
17. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010, 60:222-243. 10.3322/caac.20075, 2919227, 20554717.
18. Lee LW, Mapp AK. Transcriptional switches: chemical approaches to gene regulation. J Biol Chem 2010, 285:11033-11038. 10.1074/jbc.R109.075044, 2856975, 20147748.
19. Cook KM, Hilton ST, Mecinovic J, Motherwell WB, Figg WD, Schofield CJ. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem 2009, 284:26831-26838. 10.1074/jbc.M109.009498, 2785371, 19589782.
20. Henchey LK, Kushal S, Dubey R, Chapman RN, Olenyuk BZ, Arora PS. Inhibition of hypoxia inducible factor 1-transcription coactivator interaction by a hydrogen bond surrogate alpha-helix. J Am Chem Soc 2009, 132:941-943.
21. Lepper ER, Ng SS, Gutschow M, Weiss M, Hauschildt S, Hecker TK, Luzzio FA, Eger K, Figg WD. Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. J Med Chem 2004, 47:2219-2227. 10.1021/jm0304820, 15084120.
22. Kushal S, Wang H, Laszlo CF, Szabo LZ, Olenyuk BZ. Inhibition of hypoxia-inducible transcription factor complex with designed epipolythiodiketopiperazine. Biopolymers 2009, 95:8-16.
23. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, Memmert K, Naegeli HU, Petersen F, Eck MJ, Bair KW, Wood AW, Livingston DM. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004, 6:33-43. 10.1016/j.ccr.2004.06.009, 15261140.
24. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000, 6:1335-1340. 10.1038/82146, 11100117.
25. Li M, Liu C, Bin J, Wang Y, Chen J, Xiu J, Pei J, Lai Y, Chen D, Fan C, Xie J, Tao Y, Wu P. Mutant hypoxia inducible factor-1alpha improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle. Microvasc Res 2011, 81:26-33. 10.1016/j.mvr.2010.09.008, 20937289.
26. Lee YM, Lim JH, Yoon H, Chun YS, Park JW. Antihepatoma activity of chaetocin due to deregulated splicing of hypoxia-inducible factor 1alpha pre-mRNA in mice and in vitro. Hepatology 2011, 53:171-180. 10.1002/hep.24010, 21140472.
27. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371. 10.1038/nrm1911, 16633338.
28. Pages G, Pouyssegur J. Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors. Cardiovasc Res 2005, 65:564-573. 10.1016/j.cardiores.2004.09.032, 15664382.
29. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996, 271:32529-32537. 10.1074/jbc.271.51.32529, 8955077.
30. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998, 49:407-424. 10.1146/annurev.med.49.1.407, 9509272.
31. Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 2007, 109:2579-2588. 10.1182/blood-2006-07-027326, 1852204, 17090648.
32. Vigushin DM, Mirsaidi N, Brooke G, Sun C, Pace P, Inman L, Moody CJ, Coombes RC. Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo. Med Oncol 2004, 21:21-30. 10.1385/MO:21:1:21, 15034210.
33. Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 1990, 63:115-122.
34. Lee HJ, Lee JH, Hwang BY, Kim HS, Lee JJ. Anti-angiogenic activities of gliotoxin and its methylthioderivative, fungal metabolites. Arch Pharm Res 2001, 24:397-401. 10.1007/BF02975182, 11693538.
35. Peng G, Ren Y, Sun X, Zhou J, Li D. Inhibition of farnesyltransferase reduces angiogenesis by interrupting endothelial cell migration. Biochem Pharmacol 2012, 83:1374-1382. 10.1016/j.bcp.2012.02.008, 22382068.
36. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994, 269:23757-23763.